Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
LETTER
Gang Wang, Jie Li, Leixi Xue, Zhichun Liu
No abstract text is available yet for this article.
March 30, 2023: Clinical and Experimental Rheumatology
#2
EDITORIAL
Loïc Guillevin
No abstract text is available yet for this article.
March 30, 2023: Clinical and Experimental Rheumatology
#3
REVIEW
Francesco Reggiani, Vincenzo L'Imperio, Marta Calatroni, Fabio Pagni, Renato Alberto Sinico
Anti-glomerular basement membrane (anti-GBM) disease is a rare life-threatening small vessel vasculitis that typically affects the capillaries of kidneys and lungs, with most of patients developing rapidly progressive crescentic glomerulonephritis, and 40%-60% concomitant alveolar haemorrhage. It is caused by the deposition in alveolar and glomerular basement membrane of circulating autoantibodies directed against antigens intrinsic to the basement membrane. The exact mechanism that induces the formation of autoantibodies is unknown, but probably environmental factors, infections or direct damage to kidneys and lungs may trigger the autoimmune response in genetically susceptible individuals...
March 30, 2023: Clinical and Experimental Rheumatology
#4
JOURNAL ARTICLE
Ziyan Chen, Zixue Cheng, Zhicheng Tang, Mei Li, Xiaojun Tang, Huayong Zhang, Lingyun Sun
OBJECTIVES: Bone erosion in rheumatoid arthritis (RA) is partly caused by excessive activation of osteoclasts. Osteoclasts can be derived from RA synovium and their differentiation can be inhibited by osteoprotegerin (OPG), a decoy receptor of the osteoclastogenesis-promoting cytokine receptor activator of nuclear factor κB ligand (RANKL). Fibroblast-like synoviocytes (FLSs) are the main stromal cells in the synovium that can secret OPG. The OPG secretion of FLSs can be modulated by various cytokines...
March 27, 2023: Clinical and Experimental Rheumatology
#5
EDITORIAL
Mahmut Kaymakci, Kenneth J Warrington
No abstract text is available yet for this article.
March 27, 2023: Clinical and Experimental Rheumatology
#6
EDITORIAL
Miguel Angel González-Gay, Esther F Vicente-Rabaneda, Elena Heras-Recuero, Santos Castañeda
No abstract text is available yet for this article.
March 27, 2023: Clinical and Experimental Rheumatology
#7
JOURNAL ARTICLE
Qilin Chen, Qingdi Geng, Xinxin Yu, Fangyi Lu, Jiaoran Li, Huaxiang Liu
OBJECTIVES: Although tofacitinib has been confirmed to have good efficacy and safety in the treatment of rheumatoid arthritis (RA), the relevant mechanism at the whole transcriptome level has not yet been revealed. In this study, peripheral blood mononuclear cells (PBMCs) from patients with active RA before and after tofacitinib treatment were analysed using whole transcriptome sequencing technology. METHODS: Fourteen patients with active RA were selected to detect the alterations of mRNAs, lncRNAs, circRNAs, and miRNAs in PBMCs before and after tofacitinib treatment using whole transcriptome sequencing...
March 27, 2023: Clinical and Experimental Rheumatology
#8
JOURNAL ARTICLE
Sung Soo Ahn, Minkyung Han, Inkyung Jung, Hyung Woo Kim
OBJECTIVES: Janus kinase inhibitors and biologics (JAKi/biologics) are cornerstone treatments for rheumatoid arthritis (RA). We evaluated the risks of cancers and cardiovascular diseases (CVDs) in patients with seropositive RA (SPRA) treated with JAKi/biologics. METHODS: Patients with new-onset SPRA during 2010-2020 in the national healthcare database were identified. Events of overall and site-specific cancers, as well as CVD outcomes, including deep vein thrombosis, pulmonary embolism, and composite cardiovascular events, were investigated...
March 27, 2023: Clinical and Experimental Rheumatology
#9
JOURNAL ARTICLE
Gozde Kubra Yardimci, Christian Pagnoux, Jon Stewart
OBJECTIVES: Although management of vasculitis has evolved over the last decades, glucocorticoids (GC) have remained the cornerstone of treatment. The side effects (SE) of GC are well known by the clinicians; their importance for patients with vasculitis has not been investigated as extensively as in other rheumatological conditions. METHODS: An online questionnaire surveyed between April 29th. to July 31st, 2022 with Vasculitis Foundation Canada about the patient experience and SE of prednisone...
March 27, 2023: Clinical and Experimental Rheumatology
#10
EDITORIAL
Francesca Romana Spinelli, Marcello Govoni, Florenzo Iannone, Marta Mosca, Alberto Cauli, Bruno Frediani, Roberto Caporali, Fabrizio Conti
No abstract text is available yet for this article.
March 27, 2023: Clinical and Experimental Rheumatology
#11
JOURNAL ARTICLE
Tae Geom Lee, Taejun Yoon, Eunhee Ko, Jung Yoon Pyo, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee
OBJECTIVES: This study investigated whether soluble Tyro-3 (sTyro-3), sAxl, and sMer could reflect the current activity in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). METHODS: This study retrospectively reviewed the medical records of 76 patients with MPA and GPA, and measure the serum concentrations of sTyro-3, sAxl, and sMer using the stored serum at AAV diagnosis. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices included Birmingham vasculitis activity index (BVAS), five-factor score, the short-form 36-item health survey, and vasculitis damage index...
March 27, 2023: Clinical and Experimental Rheumatology
#12
LETTER
Miguel Ángel González-Gay, José Luis Hernández, Ricardo Blanco
No abstract text is available yet for this article.
March 21, 2023: Clinical and Experimental Rheumatology
#13
LETTER
Max Guarda, Philip A Araoz, Umar Ghaffar, Kenneth J Warrington, Matthew J Koster
No abstract text is available yet for this article.
March 20, 2023: Clinical and Experimental Rheumatology
#14
JOURNAL ARTICLE
Tânia Santiago, Mariana Santiago, Sónia Moreira, Lèlita Santos, Maria João Salvador, José António Pereira da Silva
OBJECTIVES: To examine the influence of contextual factors upon the evaluation of skin thickness and stiffness by ultrasound and to assess the reliability of these parameters. METHODS: Ultrasound dermal thickness (by B-mode, 18MHz) and skin stiffness (by shear-wave elastography, 9MHz) were assessed in persons with systemic sclerosis (SSc) and in healthy controls. The influence of contextual factors upon repeated measures was evaluated: (i) room temperature (16-17ºC vs...
March 20, 2023: Clinical and Experimental Rheumatology
#15
JOURNAL ARTICLE
Yixuan Liu, Liuxiong Guo, Wei Lin, Xiaoran Ning, Meilu Liu, Jingjing Cao, Yashuang Su, Xiao Zheng, Shuo Li, Fang Li, Luping Ren, Guangyao Song
OBJECTIVES: To investigate the clinical manifestations, immunological characteristics, circulating lymphocyte subsets and risk factors of anticentromere antibody (ACA) positive patients with primary Sjögren's syndrome (pSS). METHODS: Data of 333 patients with newly diagnosed pSS were collected and analysed retrospectively. The demographic features, glandular dysfunction, extraglandular manifestations, laboratory data, peripheral blood lymphocyte profiles and serum cytokines were compared between ACA-positive and ACA-negative pSS patients...
March 16, 2023: Clinical and Experimental Rheumatology
#16
JOURNAL ARTICLE
Ling Xiang, Andrea Hsiu Ling Low, Ying-Ying Leung, Warren Fong, Wee-Hoe Gan, Nicholas Graves, Mihir Gandhi, Julian Thumboo
OBJECTIVES: Reduced work productivity (WP), measured by work productivity loss (WPL) and work disability (WD), is common in patients with inflammatory arthritis (IA) and osteoarthritis (OA) but is not well characterised. We aimed to assess if there were any improvements in WP (WPL and WD) from diagnosis (T1) to six months later (T2) and to explore associations between WP at T2 and health status at T1 among these patients. METHODS: Patients were surveyed for work characteristics, work ability, WP and health status including physical functioning and vitality at T1 and T2...
March 16, 2023: Clinical and Experimental Rheumatology
#17
LETTER
Ivette Cruz-Bautista, Paloma Almeda-Valdés, Guadalupe López-Carrasco, Neftalí Antonio-Villa, Carlos Núñez-Álvarez, Carlos Aguilar-Salinas, Gabriela Hernandez-Molina
No abstract text is available yet for this article.
March 16, 2023: Clinical and Experimental Rheumatology
#18
JOURNAL ARTICLE
Dženan Mašić, Kristian Stengaard-Pedersen, Brian Bridal Løgstrup, Kim Hørslev-Petersen, Merete Lund Hetland, Peter Junker, Mikkel Østergaard, Claus Henrik Nielsen, Mogens Kruhøffer, Mathias Emil Bøgebjerg, Richard Röttger, Robin Christensen, Torkell Ellingsen
OBJECTIVES: To compare plasma levels of 92 cardiovascular- and inflammation-related proteins (CIRPs) and to analyse for associations with anti-cyclic citrullinated peptide (anti-CCP) status and disease activity in early and treatment-naive rheumatoid arthritis (RA). METHODS: Olink CVD-III-panel was used to measure 92 CIRP plasma levels in 180 early, treatment-naive, and highly inflamed RA patients from the OPERA trial. CIRP plasma levels as well as correlation between CIRP plasma levels and RA disease activity were compared between anti-CCP groups...
March 16, 2023: Clinical and Experimental Rheumatology
#19
Rosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, Chiara Cardamone, Paola Triggianese, Silvia Aguilera, Jeanette Andersen, Tadej Avcin, Karelle Benistan, George Bertsias, Alessandra Bortoluzzi, Coralie Bouillot, Inita Bulina, Gerd R Burmester, Steven Callens, Patricia E Carreira, Ricard Cervera, Maurizio Cutolo, Laura Damian, Emanuel Della-Torre, Raquel Faria, João E Fonseca, Ilaria Galetti, Eric Hachulla, Luca Iaccarino, Søren Jacobsen, Nikita Khmelinskii, Maarten Limper, Diana Marinello, Alain Meyer, Gianluca Moroncini, Gyorgy Nagy, Marzena Olesinska, Cristina Pamfil, Margarita Pileckyte, Mauro Pistello, Simona Rednic, Christophe Richez, Vasco C Romão, Matthias Schneider, Savino Sciascia, Carlo Alberto Scirè, Gabriele Simonini, Vanessa Smith, Alberto Sulli, Chiara Tani, Sander W Tas, Angela Tincani, Madelon C Vonk, Maria Tektonidou, Marta Mosca
Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered...
March 14, 2023: Clinical and Experimental Rheumatology
#20
LETTER
Nikolas Ruffer, Martin Krusche, Konstanze Holl-Ulrich, Ina Kötter
No abstract text is available yet for this article.
March 10, 2023: Clinical and Experimental Rheumatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
